![ISPOR Europe 2024 – May 5-8. Register now.]({"type":"image" , "src" : "/sda/112342/JournalAd-ISPOR-2024-Leaderboard.jpg"})
References
- Grossman J. One airway, one disease. Chest 1997;111(2):S11–6
- McTavish D, Sorkin EM. Azelastine – a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential. Drugs 1989;38(5):778–800
- McNeely W, Wiseman LR. Intranasal azelastine – a review of its efficacy in the management of allergic rhinitis. Drugs 1998;56(1):91–114
- McClellan K, Jarvis B. Desloratadine. Drugs 2001;61(6):789–96
- Horak F, Jäger S. The Vienna Challenge Chamber – a new method of allergen exposition test. Wien Klin Wochenschr 1987;99(14):509–10
- Day JH, Briscoe MP. Environmental exposure unit: a system to test anti-allergic treatment. Ann Allergy Asthma Immunol 1999;83:83–93
- Horak F, Stübner P, Zieglmayer R, et al. Controlled comparison of the efficacy and safety of cetirizine 10 mg o.d. and fexofenadine 120 mg o.d. in reducing symptoms of seasonal allergic rhinitis. Int Arch Allergy Immunol 2001;125:73–9
- Horak F, Stübner UP, Zieglmayer R, et al. Effect of desloratadine versus placebo on nasal airflow and subjective measures of nasal obstruction in subjects with grass pollen-induced allergic rhinitis in an allergen-exposure unit. J Allergy Clin Immunol 2002;109(6):956–61
- Murdoch D, Goa KL, Keam SJ. Desloratadine – an update of its efficacy in the management of allergic disorders. Drugs 2003;63(19):2051–77
- Thomas KE, Ollier S, Ferguson H, et al. The effect of intranasal azelastine, RhinolastÒ, on nasal airway obstruction and sneezing following provocation testing with histamine and allergen. Clin Exp Allergy 1992;22:642–7
- Horak F, Jäger S, Toth J, et al. Azelastine in pollen-induced allergic rhinitis – a pharmacodynamic study of onset of action and efficacy. Drug Invest 1994;7(1):34–40
- Baumgarten CR, Petzold U, Dokic D, et al. Modification of allergen-induced symptoms and mediator release by intranasal azelastine. J Pharmacol Ther 1994;3(2):43–51
- Ciprandi G, Pronzato C, Passalacqua G, et al. Topical azelastine reduces eosinophil activation and intercellular adhesion molecule-1 expression on nasal epithelial cells: an antiallergic activity. J Allergy Clin Immunol 1996;98(6):1088–96
- Dykewicz MS, Fineman S, Skoner DP, et al. Diagnosis and management of rhinitis: complete guidelines of the joint task force on practice parameters in allergy, asthma and immunology. Ann Allerg Asthma Immunol 1998;81:478–518
- Horak F, Stübner UP, Zieglmayer R, et al. Onset and duration of action of desloratadine after controlled pollen challenges in patients with seasonal allergic rhinitis [Abstract 1000]. Allergy 2000;55(63):S279
- Horak F, Stübner P. Decongestant activity of desloratadine in controlled-allergen-exposure trials. Clin Drug Invest 2002;22(Suppl 2):13–20